Omalizumab effective for chronic spontaneous urticaria

Omalizumab effective for chronic spontaneous urticaria

(HealthDay)—Omalizumab, alone or in combination with a short-term course of corticosteroids, is highly effective for the treatment of refractory chronic spontaneous urticaria (CSU), according to a study published online Feb. 5 in the International Journal of Dermatology.

Nikolaos Syrigos, M.D., from Sotiria General Hospital in Athens, Greece, and colleagues retrospectively evaluated from 20 (mean age 54.5 years; 75 percent women) with refractory CSU in order to assess correlations between demographic, clinical, and laboratory characteristics and omalizumab treatment outcomes.

The researchers found that mean disease duration before omalizumab administration was 21.8 months. All patients responded favorably to omalizumab after one to five doses, with 85 percent of patients having a complete response. The remaining three patients had well-controlled disease after omalizumab treatment. In 30 percent of patients, the best response to omalizumab was achieved after interval administration of a nine-day course of methylprednisolone (total dose of 188 mg). A shorter disease duration before initiation of omalizumab was significantly correlated with late response to omalizumab (after three-month treatment).

"In the present series, , either alone or in combination with a short-term course of corticosteroids, was highly effective in resolution of refractory CSU," the authors write.


Explore further

Intranasal omalizumab does not increase serum IgE levels

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2018 HealthDay. All rights reserved.

Citation: Omalizumab effective for chronic spontaneous urticaria (2018, February 13) retrieved 1 April 2020 from https://medicalxpress.com/news/2018-02-omalizumab-effective-chronic-spontaneous-urticaria.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments